A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand

BACKGROUND: Hemophilia patients use factor-clotting concentrates (factor VIII for hemophilia A and factor IX for hemophilia B) for improved blood clotting. These products are used to prevent or stop bleeding episodes. However, some hemophilia patients develop inhibitors (i.e., the patient’s immune s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Darshan A., Oladapo, Abiola O., Epstein, Joshua D., Novack, Aaron R., Neufeld, Ellis J., Hay, Joel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397845/
https://www.ncbi.nlm.nih.gov/pubmed/27015254
http://dx.doi.org/10.18553/jmcp.2016.22.2.149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397845/
https://www.ncbi.nlm.nih.gov/pubmed/27015254
http://dx.doi.org/10.18553/jmcp.2016.22.2.149

Ejemplares similares